Here are relevant reports on : stem-cell-therapy-market
-
Tissue Engineering Market by Product (Scaffolds (Collagen, Stem Cell), Tissue Grafts (Allograft, Autograft, Xenograft)), Material (Biological, Synthetic), Application (Orthopedics, Dermatology, Wound Care, Cardiovascular) - Global Forecast to 2028
The global tissue engineering market, valued at US$4.3 billion in 2022, stood at US$4.4 billion in 2023 and is projected to advance at a resilient CAGR of 15.3% from 2023 to 2028, culminating in a forecasted valuation of US$8.9 billion by the end of the period. The growth of this market is largely driven by the emergence of promising technologies, including 3D bioprinting, and rising demand for advanced solutions for damaged tissue repair and regeneration.
- Published: December 2023
- Price: $ 4950
- TOC Available:
-
Apoptosis Assays Market by Product (Caspase, Annexin V, DNA Fragmentation, Mitochondrial Assay), Detection Technology (Flow Cytometry, Florescence microscopy), Application (Stem Cell, Discovery & Development, Clinical Research) & Region - Global Forecasts to 2023
The global apoptosis assays market is projected to reach USD 5.9 billion by 2023, at a CAGR of 10.5%. The prominent players in the apoptosis assays market are Merck KGaA (Germany), Thermo Fisher Scientific (US), Bio-Rad Laboratories (US), Becton, Dickinson and Company (US), GE Healthcare (US), Sartorius AG (Germany), Danaher Corporation (US), Geno Technology (US), GeneCopoeia, Inc. (US), Bio-Techne Corporation(US), BioTek Instruments (US), PerkinElmer (US), Promega Corporation (US), Biotium (US), Abcam plc (UK), Canvax (Spain), Abnova (Taiwan), and Creative Bioarray (US).
- Published: November 2018
- Price: $ 4950
- TOC Available:
-
Autologous Stem Cell & Non-stem Cell Therapies Market by Type (CAR-T, Tumor Infiltrating Lymphocyte), Indication (Cancer, Musculoskeletal, Dermatology), Source (T-Cells, Mesenchymal Stem Cell), End User (Hospital) & Region - Global Forecast to 2029
The global autologous stem cell & non-stem cell therapies market, valued at US$3.9 billion in 2023, stood at US$5.5 billion in 2024 and is projected to advance at a resilient CAGR of 32.3% from 2024 to 2029, culminating in a forecasted valuation of US$22.2 billion by the end of the period. The major factors driving the growth of this market are the rising regulatory approvals for autologous CAR T cell therapies, increasing R&D investments in autologous therapeutics, and growing demand for personalized medicines.
- Published: June 2024
- Price: $ 4950
- TOC Available:
-
Fill Finish Manufacturing Market by Consumables (PFS [System, Plunger Stoppers, Glass, Polymer], Vials [Bulk, RTU], Vial Stoppers, Cartridges, Cell Therapy Bags), Instruments (Integrated), Type (Automated), Services, Competition - Global Forecast to 2031
The global fill finish manufacturing market is projected to reach USD 30.37 billion by 2031, growing at a CAGR of 9.0% during the forecast period (2026–2031). The report covers key segments, regional analysis, and competitive landscape across the market ecosystem.
- Published: June 2026
- Price: $ 4950
- TOC Available:
-
Leukapheresis Market by Type (Filter, Membrane Separator, Centrifugal Device), Leukopak (Mobilized, Isolated PBMC), Application (Research [Cell & Gene Therapy, Transplantation], Therapeutic), Indication, End User, Region - Global Forecast to 2031
The global Leukapheresis market, valued at USD 83.3 billion in 2025, stood at USD 90.6 billion in 2026 and is projected to advance at a resilient CAGR of 8.9% from 2026 to 2031, culminating in a forecasted valuation of USD 138.7 billion by the end of the period. This growth is driven by the increasing number of therapeutic and manufacturing applications for leukapheresis in hematologic disorders, as well as the rising demand for high-quality starting materials used in cell and gene therapy, including CAR-T, TCR, and NK-cell programs.
- Published: June 2026
- Price: $ 4950
- TOC Available:
-
CAR T-Cell Therapy Market by Product (Abecma, Breyanzi, Carvykti, Yescarta, Tecartus, Kymriah), Target (CD19, BCMA), Indication (Multiple Myeloma, Leukemia, Lymphoma), Demographic (Adult, Pediatric), Region, Competitive Landscape - Global Forecast to 2031
The global CAR T-cell therapy market, valued at USD 5.98 billion in 2025, stood at USD 6.78 billion in 2026 and is projected to advance at a resilient CAGR of 14.9% from 2026 to 2031, culminating in a forecasted valuation of USD 13.56 billion by the end of the period. The global CAR T-cell therapy market is growing due to rapid technological advances alongside rising investments from large pharma and well-funded biotech's.
- Published: February 2026
- Price: $ 4950
- TOC Available:
-
Continuous Bioprocessing Market by Product (Chromatography, Filtration, Bioreactor, Media), Process (Upstream, Downstream), Scale of Operation (Commercial, Clinical), Application (mAbs, Vaccines, Cell & Gene Therapy), & End User - Global Forecast to 2028
The global continuous bioprocessing market, valued at US$201 million in 2022, stood at US$218 million in 2023 and is projected to advance at a resilient CAGR of 22.4% from 2023 to 2028, culminating in a forecasted valuation of US$599 million by the end of the period. The growth of the market is largely driven by rising demand for biopharmaceuticals, advantages of continuous bioprocessing over batch/fed-batch mode, and emergence of integrated end-to-end continuous bioprocessing.
- Published: November 2023
- Price: $ 4950
- TOC Available:
-
Recombinant Proteins Market by Product (Growth Factors, Chemokines, Structural Proteins, Membrane Proteins), Application (Drug Discovery & Development (Biologics, Vaccines, Cell & Gene Therapy), Research, Biopharma Production) & Region - Global Forecast to 2028
The global recombinant proteins market, valued at US$2.1 billion in 2022, stood at US$2.2 billion in 2023 and is projected to advance at a resilient CAGR of 7.2% from 2023 to 2028, culminating in a forecasted valuation of US$3.2 billion by the end of the period. Growth in the market can be attributed to factors such as rising incidence of chronic diseases, growing demand for biologics and biosimilars due to expiration of patents, rising demand for customized medicine and increasing government initiatives for R&D in life sciences research.
- Published: January 2024
- Price: $ 4950
- TOC Available:
-
Viral Vector & Plasmid DNA Manufacturing Market by Type (Viral Vector (Retroviruses, Adenoviruses, AAV, Lentiviruses), Plasmid DNA), Workflow (Upstream, Downstream), Application (Cell & Gene Therapy), Diseases (Cancer), End User - Global Forecast to 2028
The global viral vector manufacturing market, valued at US$4.8 billion in 2022, stood at US$5.5 billion in 2023 and is projected to advance at a resilient CAGR of 18.2% from 2023 to 2028, culminating in a forecasted valuation of US$12.8 billion by the end of the period. The growth of this market is majorly driven by g rising prevalence of target diseases and disorders, the availability of funding for gene therapy development, and effectiveness of viral vectors in gene therapy delivery.
- Published: June 2023
- Price: $ 4950
- TOC Available:
-
Companion Diagnostics Market by Product (Assays, Kits, & Reagents, Instruments, Software), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Lung, Colorectal Cancer, CVD, Infectious), Drug Class (MAB, Cell & Gene Therapy) - Global Forecast to 2031
The global companion diagnostics market is projected to reach USD 11.57 billion by 2031, growing at a CAGR of 12.9% during the forecast period (2026–2031). The report covers key segments, regional analysis, and competitive landscape across the market ecosystem.
- Published: June 2026
- Price: $ 4950
- TOC Available:
Records 21 to 30 of 50
